Strides Pharma Science Ltd (IN:STAR)
:STAR
Top Page
Strides Pharma Science Ltd
(STAR)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹943.00
▼(-0.82% Downside)
Action:ReiteratedDate:01/31/26
The score is driven primarily by improving financial performance and healthy cash generation, tempered by historical earnings volatility and some balance sheet constraints. Technicals are a secondary drag due to weak trend signals (negative MACD and price below key moving averages), while valuation is supportive with a reasonable P/E and modest yield.
Positive Factors
Strong free cash flow generation
Consistent conversion of earnings into free cash flow improves financial resilience and funds capital spending, regulatory compliance, and working capital without reliance on external financing. This durable cash generation supports reinvestment in manufacturing capacity and product development over several quarters.
Negative Factors
Historical earnings volatility
Past swings into negative EBIT/EBITDA indicate execution and margin risk that can persist through product lifecycle shifts or tender losses. Such volatility undermines predictability for capex planning and sustained R&D spend, increasing the difficulty of delivering stable long-term cash flows and returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow generation
Consistent conversion of earnings into free cash flow improves financial resilience and funds capital spending, regulatory compliance, and working capital without reliance on external financing. This durable cash generation supports reinvestment in manufacturing capacity and product development over several quarters.
Read all positive factors
Strides Pharma Science Ltd (STAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹86.59B
Dividend Yield0.41%
Average Volume (3M)12.54K
Price to Earnings (P/E)10.3
Beta (1Y)0.94
Revenue Growth6.22%
EPS Growth123.83%
CountryIN
Employees3,065
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)21.90
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.40
Price to Sales (P/S)1.37
P/FCF Ratio13.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)60.95
Revenue Forecast (FY)₹48.28B
Strides Pharma Science Ltd Business Overview & Revenue Model
Company Description
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The com...
How the Company Makes Money
Strides Pharma Science Ltd generates revenue through multiple key streams, including the sale of generic pharmaceuticals, where it offers a portfolio of high-quality, affordable medications across various therapeutic categories. The company also e...
Strides Pharma Science Ltd Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.85B | 44.75B | 38.28B | 36.68B | 30.59B | 32.80B |
| Gross Profit | 16.59B | 11.83B | 8.51B | 8.05B | 4.11B | 9.59B |
| EBITDA | 8.78B | 7.10B | 5.15B | 3.66B | -214.95M | 5.17B |
| Net Income | 3.97B | 4.05B | -1.20B | -2.21B | -4.60B | 2.55B |
Balance Sheet | ||||||
| Total Assets | 65.21B | 60.49B | 58.40B | 66.38B | 69.76B | 70.15B |
| Cash, Cash Equivalents and Short-Term Investments | 2.27B | 2.06B | 2.90B | 3.61B | 1.84B | 2.75B |
| Total Debt | 18.44B | 18.80B | 25.17B | 30.30B | 30.25B | 23.48B |
| Total Liabilities | 37.18B | 34.62B | 37.68B | 44.66B | 45.93B | 42.01B |
| Stockholders Equity | 27.56B | 25.52B | 21.26B | 22.12B | 23.59B | 27.77B |
Cash Flow | ||||||
| Free Cash Flow | 2.42B | 4.42B | 5.83B | -505.27M | -4.01B | 1.84B |
| Operating Cash Flow | 3.91B | 6.84B | 7.01B | 444.11M | -2.58B | 4.81B |
| Investing Cash Flow | -1.48B | -896.89M | -1.50B | 3.02B | -1.19B | -5.21B |
| Financing Cash Flow | -2.33B | -6.43B | -6.93B | -2.14B | 4.21B | -157.96M |
Strides Pharma Science Ltd Technical Analysis
Positive
950.75
Price Trends
872.15
Positive
895.94
Positive
877.65
Positive
Market Momentum
14.49
Negative
64.65
Neutral
74.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:STAR, the sentiment is Positive. The current price of 950.75 is above the 20-day moving average (MA) of 886.24, above the 50-day MA of 872.15, and above the 200-day MA of 877.65, indicating a bullish trend. The MACD of 14.49 indicates Negative momentum. The RSI at 64.65 is Neutral, neither overbought nor oversold. The STOCH value of 74.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:STAR.
Strides Pharma Science Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹763.03B | 18.87 | ― | 0.33% | 7.33% | -3.79% | |
73 Outperform | ₹401.71B | 27.58 | ― | 0.28% | 9.66% | 25.79% | |
72 Outperform | ₹638.90B | 25.97 | ― | 0.80% | 9.32% | 11.25% | |
66 Neutral | ₹544.88B | 59.42 | ― | 0.15% | 25.83% | 421.20% | |
65 Neutral | ₹86.59B | 10.27 | ― | 0.41% | 6.22% | 123.83% | |
53 Neutral | ₹612.52B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:STAR
Strides Pharma Science Ltd
939.40
274.30
41.24%
IN:ALKEM
Alkem Laboratories Ltd.
5,343.50
510.48
10.56%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,313.75
183.15
16.20%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,170.50
665.44
44.21%
IN:IPCALAB
IPCA Laboratories Limited
1,583.65
192.38
13.83%
IN:LAURUSLABS
Laurus Labs Ltd.
1,009.30
412.26
69.05%
Strides Pharma Science Ltd Corporate Events
Strides Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts
Jan 31, 2026
Strides Pharma Science Ltd has published extracts of its unaudited financial results for the quarter and nine months ended 31 December 2025 in the Financial Express and Lokmat newspapers, in line with regulatory disclosure requirements. The compan...
Strides Pharma Closes Trading Window Ahead of December Quarter Results
Dec 22, 2025
Strides Pharma Science Limited has announced that its trading window for dealing in the company’s shares will be closed from January 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations, 2015 and the company’s ...
Strides Pharma Releases Earnings Call Audio for Q2 FY26
Oct 31, 2025
Strides Pharma Science Ltd announced the availability of the audio recording of its earnings call discussing the unaudited financial results for the quarter and half year ended September 30, 2025. This move is part of their compliance with SEBI re...
Strides Pharma Releases Earnings Call Audio for Q2 FY26
Oct 31, 2025
Strides Pharma Science Limited announced the availability of the audio recording of its earnings call discussing the unaudited financial results for the quarter and half year ended September 30, 2025. This update is significant for stakeholders as...
Strides Pharma Releases Unaudited Financial Results for September 2025
Oct 31, 2025
Strides Pharma Science Limited has released its unaudited financial results for the quarter and half-year ending September 30, 2025. The results, approved by the Board of Directors, were submitted to the stock exchanges in compliance with SEBI reg...
Strides Pharma Achieves Record Quarterly EPS in Q2FY26
Oct 31, 2025
Strides Pharma Science Ltd reported its highest-ever quarterly earnings per share (EPS) for Q2FY26, with an operational profit after tax (PAT) of ₹1,403 million and an EPS of ₹15.2, marking an 84% year-on-year growth. The company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.